VERAXA & OmniAb Partner for Bispecific ADC Program

ZURICH, SWITZERLAND, May 5, 2025 -- VERAXA Biotech AG (proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ: VACH)), announced a co-discovery alliance with OmniAb, Inc. (NASDAQ: OABI) for a novel bispecific antibody drug conjugate (“bsADC”) program targeting solid tumors. The collaboration combines OmniAb’s antibody discovery solutions with VERAXA’s ADC linker technology.

Christoph Antz, Ph.D., CEO and Co-Founder of VERAXA, stated that the partnership brings together complementary technologies to create a new class of bispecific ADCs, representing an opportunity to address difficult-to-treat solid tumors. He added that strategic collaborations will continue to be a mainstay in VERAXA’s pipeline growth strategy.

... Read on — Members only